|Articles|December 2, 2021
Pharmacy Clinical Pearl of the Day: Churg-Strauss Syndrome
Author(s)Saro Arakelians, PharmD
Churg-Strauss syndrome causes inflammation that can restrict blood flow to organs and tissues.
Advertisement
Clinical Pearl of the Day: Churg-Strauss Syndrome
Churg-Strauss syndrome is a disorder marked by blood vessel inflammation.
Insight:
- This inflammation can restrict blood flow to organs and tissues, sometimes permanently damaging them.
- This condition is also known as eosinophilic granulomatosis with polyangiitis (EGPA).
- Adult-onset asthma is the most common sign of Churg-Strauss syndrome.
- Symptoms may include loss of appetite, weight loss, joint and muscle pain, abdominal pain, weakness, fatigue, rash, skin sores, pain, numbness and tingling in the hands and feet.
- Complications may include peripheral nerve damage, heart disease, and kidney damage.
- Diagnosis may include blood test, imaging tests, and biopsy of the affected tissue.
- Treatment may include corticosteroids, such as Prednisone, to reduce inflammation; Mepolizumab (Nucala); and other medications such as azathioprine (Azasan, Imuran), benralizumab (Fasenra), cyclophosphamide, methotrexate (Trexall), and rituximab (Rituxan).
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Articles
- IMS 2025: Improving Outcomes with Bispecifics in Multiple Myeloma
September 19th 2025
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
Elranatamab Plus Daratumumab and Lenalidomide Yields Durable Responses, Manageable Safety
2
Effectively Managing Immunizations in the Long-Term Care Setting
3
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
4
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
5